{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:47:43Z","timestamp":1774442863316,"version":"3.50.1"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Chromosomal rearrangements involving the Mixed lineage leukemia\n(MLL) gene are observed in acute leukemia (AL) patients, which have poor prognosis, especially\nin infants. Hence, there is still a challenge to develop other effective agents to treat AL with MLL\nrearrangements (MLLr). MLL has been shown to rearrange with partner genes, of which the most\nfrequently observed are AF4 and AF9. Moreover, AL is characterized by a differentiation blockage\nresulting in the accumulation of immature cells. An ent-kaurene diterpenoid compound, Jiyuan\nOridonin A (JOA), has been shown to reduce the viability of AML cells by differentiation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We aimed to evaluate the effect of JOA on the growth and differentiation of AL cells\n(SEM, JURKAT and MV4-11) including cells with MLLr-AF4 by cell proliferation assay, colony\nformation assay, cell cycle analysis, cell apoptosis analysis, measurement of cell surface\nantigens and cell morphology, mRNA-sequencing analysis, quantitative Real-time PCR and\nWestern blotting analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Our findings demonstrated that the proliferation of AL cells including cells with\nMLLr-AF4 was significantly suppressed by JOA, which induced cell differentiation followed\nby G0\/G1 cell cycle withdrawal. Moreover, JOA-mediated cell differentiation was likely due to\nactivation of G-CSFR in MV4-11 cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our results suggest that JOA may be considered a promising anti-leukemia compound\nto develop to surmount the differentiation block in AL patients<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748928263141231204112640","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T07:01:43Z","timestamp":1704956503000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differentiation of Acute Leukemia Cells Including Cells with MLL-AF4 Rearrangements Induced by Jiyuan Oridonin A"],"prefix":"10.2174","volume":"20","author":[{"given":"Xueming","family":"Li","sequence":"first","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglian","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ke","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Zhengzhou University,\nZhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmin","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Zhengzhou University,\nZhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenbo","family":"Hu","sequence":"additional","affiliation":[{"name":"Laboratory for Stem Cell and Regenerative Medicine, Affiliated Hospital of Shandong Weifang\nMedical University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuya","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.leukres.2020.106389","volume":"95","author":"Soto-Mercado V.","year":"2020","unstructured":"Soto-Mercado V.; Mendivil-Perez M.; Jimenez-Del-Rio M.; Fox J.E.; Velez-Pardo C.; Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism. Leuk Res  2020,95,106389","journal-title":"Leuk Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood.V128.22.576.576","volume":"128","author":"Lin S.","year":"2016","unstructured":"Lin S.; Ptasinska A.; Assi S.A.; The transcriptome heterogeneity of mll-fusion all is driven by fusion partners via distinct chromatin binding. Blood  2016,128(22),576","journal-title":"Blood"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2021-147003","volume":"138","author":"Li C.","year":"2021","unstructured":"Li C.; Wright S.; Hu J.; Zhang Y.; Hyle J.; Lu R.; Interrogating novel bromodomain inhibition resistance mechanism in mllr leukemia. Blood  2021,138(Suppl. 1),26","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","volume":"122","author":"Daigle S.R.","year":"2013","unstructured":"Daigle S.R.; Olhava E.J.; Therkelsen C.A.; Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood  2013,122(6),1017-1025","journal-title":"Blood"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12185-008-0034-2","volume":"87","author":"Tamai H.","year":"2008","unstructured":"Tamai H.; Yamaguchi H.; Hamaguchi H.; Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: A co-operative multicenter study. Int J Hematol  2008,87(2),195-202","journal-title":"Int J Hematol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"100853","DOI":"10.1016\/j.drup.2022.100853","volume":"64","author":"\u015aniegocka M.","year":"2022","unstructured":"\u015aniegocka M.; Liccardo F.; Fazi F.; Masciarelli S.; Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia. Drug Resist Updat  2022,64,100853","journal-title":"Drug Resist Updat"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"100703","DOI":"10.1016\/j.drup.2020.100703","volume":"52","author":"Long L.","year":"2020","unstructured":"Long L.; Assaraf Y.G.; Lei Z.N.; Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resist Updat  2020,52,100703","journal-title":"Drug Resist Updat"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood.V124.21.972.972","volume":"124","author":"Koss C.","year":"2014","unstructured":"Koss C.; Nance S.; Connelly M.; Targeted inhibition of the MLL transcriptional complex by proteosome inhibitors elicits a high response rate in relapsed\/refractory mll rearranged leukemia. Blood  2014,124(21),972","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.drudis.2020.01.021","volume":"25","author":"Bizzarri M.","year":"2020","unstructured":"Bizzarri M.; Giuliani A.; Cucina A.; Minini M.; Redifferentiation therapeutic strategies in cancer. Drug Discov Today  2020,25(4),731-738","journal-title":"Drug Discov Today"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"876076","DOI":"10.3389\/fphar.2022.876076","volume":"13","author":"Yao J.","year":"2022","unstructured":"Yao J.; Li G.; Cui Z.; The Histone deacetylase inhibitor i1 induces differentiation of acute leukemia cells with mll gene rearrangements via epigenetic modification. Front Pharmacol  2022,13,876076","journal-title":"Front Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ejmech.2018.08.056","volume":"157","author":"Ke Y.","year":"2018","unstructured":"Ke Y.; Liang J.J.; Hou R.J.; Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents. Eur J Med Chem  2018,157,1249-1263","journal-title":"Eur J Med Chem"},{"key":"ref=12","author":"Liu H.M.","year":"2011","unstructured":"Liu H.M.; Zhu W.C.; Zhu C.G.; Novel entkaurene diterpene compound and its derivatives, their preparation and their use.  2011"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"659720","DOI":"10.3389\/fonc.2021.659720","volume":"11","author":"Qu M.","year":"2021","unstructured":"Qu M.; Duan Y.; Zhao M.; Jiyuan oridonin A overcomes differentiation blockade in acute myeloid leukemia cells with MLL rearrangements via multiple signaling pathways. Front Oncol  2021,11,659720","journal-title":"Front Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1001552","DOI":"10.3389\/fphar.2022.1001552","volume":"13","author":"Li F.","year":"2022","unstructured":"Li F.; Gao C.; Li X.; Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells. Front Pharmacol  2022,13,1001552","journal-title":"Front Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"855570","DOI":"10.3389\/fonc.2022.855570","volume":"12","author":"Ma X.","year":"2022","unstructured":"Ma X.; Zhao M.; Wu Z.X.; The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. Front Oncol  2022,12,855570","journal-title":"Front Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.18632\/oncotarget.1816","volume":"5","author":"Hu K.","year":"2014","unstructured":"Hu K.; Liao D.; Wu W.; Targeting the anaphase-promoting complex\/cyclosome (APC\/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget  2014,5(10),3088-3100","journal-title":"Oncotarget"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2017.300","volume":"32","author":"Fujita S.","year":"2018","unstructured":"Fujita S.; Honma D.; Adachi N.; Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia  2018,32(4),855-864","journal-title":"Leukemia"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/epi.10.39","volume":"2","author":"Chatterton Z.","year":"2010","unstructured":"Chatterton Z.; Morenos L.; Saffery R.; Craig J.M.; Ashley D.; Wong N.C.; DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. Epigenomics  2010,2(5),697-708","journal-title":"Epigenomics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/1097-0142(19951215)76:12<2393:AID-CNCR2820761203>3.0.CO;2-P","volume":"76","author":"Cortes J.E.","year":"1995","unstructured":"Cortes J.E.; Kantarjian H.M.; Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy. Cancer  1995,76(12),2393-2417","journal-title":"Cancer"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.leu.2403200","volume":"18","author":"Erfurth F.","year":"2004","unstructured":"Erfurth F.; Hemenway C.S.; de Erkenez A.C.; Domer P.H.; MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia  2004,18(1),92-102","journal-title":"Leukemia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3324\/haematol.2012.081877","volume":"98","author":"Marks D.I.","year":"2013","unstructured":"Marks D.I.; Moorman A.V.; Chilton L.; The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)\/MLL-AFF1 prospectively treated in the UKALLXII\/ECOG2993 trial. Haematologica  2013,98(6),945-952","journal-title":"Haematologica"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","volume":"359","author":"Pui C.H.","year":"2002","unstructured":"Pui C.H.; Gaynon P.S.; Boyett J.M.; Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet  2002,359(9321),1909-1915","journal-title":"Lancet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","volume":"116","author":"Mann G.","year":"2010","unstructured":"Mann G.; Attarbaschi A.; Schrappe M.; Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)\u2013rearranged acute lymphoblastic leukemia: Results from the Interfant-99 Study. Blood  2010,116(15),2644-2650","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.leukres.2007.04.013","volume":"32","author":"Barber N.","year":"2008","unstructured":"Barber N.; Belov L.; Christopherson R.I.; All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leuk Res  2008,32(2),315-322","journal-title":"Leuk Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.bbamcr.2013.06.018","volume":"1833","author":"Lochab S.","year":"2013","unstructured":"Lochab S.; Pal P.; Kapoor I.; E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation. Biochim Biophys Acta Mol Cell Res  2013,1833(12),2639-2652","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1182\/blood-2003-06-1861","volume":"103","author":"Zhu Q.S.","year":"2004","unstructured":"Zhu Q.S.; Robinson L.J.; Roginskaya V.; Corey S.J.; G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood  2004,103(9),3305-3312","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/0092-8674(93)90729-A","volume":"74","author":"Fukunaga R.","year":"1993","unstructured":"Fukunaga R.; Ishizaka-Ikeda E.; Nagata S.; Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell  1993,74(6),1079-1087","journal-title":"Cell"},{"key":"ref=28","first-page":"1445","volume":"52","author":"Hass R.","year":"1992","unstructured":"Hass R.; Gunji H.; Datta R.; Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes. Cancer Res  1992,52(6),1445-1450","journal-title":"Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/cancers11091220","volume":"11","author":"Kreis N.N.","year":"2019","unstructured":"Kreis N.N.; Louwen F.; Yuan J.; The multifaceted p21 (Cip1\/Waf1\/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers  2019,11(9),1220","journal-title":"Cancers"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtn.2022.03.020","volume":"28","author":"Bi G.","year":"2022","unstructured":"Bi G.; Liang J.; Zhao M.; miR-6077 promotes cisplatin\/pemetrexed resistance in lung adenocarcinoma via CDKN1A\/cell cycle arrest and KEAP1\/ferroptosis pathways. Mol Ther Nucleic Acids  2022,28,366-386","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"Abbas T.","year":"2009","unstructured":"Abbas T.; Dutta A.; p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer  2009,9(6),400-414","journal-title":"Nat Rev Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nature03269","volume":"433","author":"Carreira S.","year":"2005","unstructured":"Carreira S.; Goodall J.; Aksan I.; Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature  2005,433(7027),764-769","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-08-3718","volume":"69","author":"Schwentner R.","year":"2009","unstructured":"Schwentner R.; Bennani-Baiti I.; Kovar H.; CDKN1A gene regulation in Ewing\u2019s sarcoma. Cancer Res  2009,69(Suppl. 9),1536","journal-title":"Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2019.03.045","volume":"453","author":"Luo J.","year":"2019","unstructured":"Luo J.; Liu K.; Yao Y.; DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell. Cancer Lett  2019,453,45-56","journal-title":"Cancer Lett"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1038\/ncomms4756","volume":"5","author":"Cazier J.B.","year":"2014","unstructured":"Cazier J.B.; Rao S.R.; McLean C.M.; Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun  2014,5(1),3756","journal-title":"Nat Commun"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928263141231204112640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225378\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928263141231204112640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:44:07Z","timestamp":1743147847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225378\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748928263141231204112640","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}